Get the Stockscreener App
112.78
1.60%
1.78
After Hours:
112.78
Biontech Se Adr stock is traded at $112.78, with a volume of 534.72K.
It is up +1.60% in the last 24 hours and down -0.10% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
See More
Previous Close:
$111.00
Open:
$111.5
24h Volume:
534.72K
Relative Volume:
0.63
Market Cap:
$27.11B
Revenue:
$2.97B
Net Income/Loss:
$-812.83M
P/E Ratio:
-33.21
EPS:
-3.3962
Net Cash Flow:
$-1.24B
1W Performance:
+1.33%
1M Performance:
-0.10%
6M Performance:
-8.14%
1Y Performance:
+36.14%
1-Day Range:
$111.50
$113.39
1-Week Range:
$108.56
$114.01
52-Week Range:
$81.20
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
112.78 | 26.68B | 2.97B | -812.83M | -1.24B | -3.3962 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
| May-29-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Benzinga
BioNTech’s Promising Lung Cancer Study: A Potential Game-Changer in Oncology - TipRanks
BioNTech’s BNT327 Study: A New Hope for Lung Cancer Treatment? - The Globe and Mail
BioNTech’s Promising Phase II Study on BNT327 for Small-cell Lung Cancer - The Globe and Mail
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
BioNTech SE’s BNT331 Safety Trial: A Potential Game-Changer in Women’s Health - TipRanks
Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer? - The Globe and Mail
BioNTech ADR Earns RS Rating Upgrade - inkl
BioNTech’s Strategic Moves and Financial Outlook - The Globe and Mail
BioNTech SE Earnings Call: Strategic Growth Amid Challenges - TipRanks
BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer? - TipRanks
Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech Earnings: Guidance Reiterated; Incremental Progress in Clinical Trials - Morningstar
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update04.08.25News - Ariva
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - The Globe and Mail
BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday - Defense World
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - Yahoo Finance
Cancer Vaccine Market Research Service Featuring the Top 5 Developers and Pipeline Activities - GlobeNewswire Inc.
Best Momentum Stocks to Buy for July 29th - Yahoo Finance
New Strong Buy Stocks for July 29th - Yahoo Finance
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Acquired by Kestra Private Wealth Services LLC - Defense World
Cerity Partners LLC Invests $357,000 in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
BioNTech’s Promising Study on Pancreatic Cancer Treatment: Market Implications - TipRanks
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - TipRanks
BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks
BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
Swansea Building Society Extends Support for Swansea City AFC - Business News Wales
BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks
BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva
BioNTech’s DYNASTY-Breast02 Study: A New Hope for Metastatic Breast Cancer? - TipRanks
OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks
BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks
BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest
Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):